Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

42.9%

6 terminated/withdrawn out of 14 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

21%

3 trials in Phase 3/4

Results Transparency

250%

5 of 2 completed trials have results

Key Signals

2 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

6(50.0%)

Phase 3

3(25.0%)

Phase 1

2(16.7%)

Early Phase 1

1(8.3%)

12Total

Phase 2(6)

Phase 3(3)

Phase 1(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT07169279Phase 2Recruiting

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

Role: lead

NCT06164951Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

Role: lead

NCT04504331Phase 1Terminated

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Role: collaborator

NCT07393373Phase 2Enrolling By Invitation

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

Role: lead

NCT06873035Phase 2Enrolling By Invitation

An Interventional Study of Infigratinib in Children With Hypochondroplasia

Role: lead

NCT05145010Phase 2Enrolling By Invitation

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Role: lead

NCT04424966Early Phase 1Terminated

Infigratinib in Recurrent High-Grade Glioma Patients

Role: collaborator

NCT04265651Phase 2Completed

Study of Infigratinib in Children With Achondroplasia

Role: lead

NCT06410976Recruiting

Prospective Clinical Assessment Study in Children With Hypochondroplasia

Role: lead

NCT04035811Active Not Recruiting

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Role: lead

NCT03773302Phase 3Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Role: lead

NCT04197986Phase 3Terminated

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Role: lead

NCT02150967Phase 2Terminated

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Role: lead

NCT04972253Phase 1Withdrawn

Phase I BLASST-3 Trial

Role: collaborator

All 14 trials loaded